PARIS–(BUSINESS WIRE)–Regulatory News:


ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023:

– 43,423 shares

– € 382,720.54

– Number of executions on buy side on semester: 631

– Number of executions on sell side on semester: 505

– Traded volume on buy side on semester: 59,726 shares for € 419,225.09

– Traded volume on sell side on semester: 50,122 shares for € 385,042.61

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2022 on the liquidity account:

– 33,819 shares

– € 412,635.83

– Number of executions on buy side on semester: 356

– Number of executions on sell side on semester: 414

– Traded volume on buy side on semester: 31,336 shares for € 191,946.13

– Traded volume on sell side on semester: 41,970 shares for € 283,671.24

  • the following resources appeared on the liquidity account when the activity started:

– 0 shares

– € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

The positive results from its Phase 1b/2a study, ACTIMIS, confirmed the safety profile and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients. In July 2022, Acticor Biotech was granted “PRIME” status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 – ALACT).

For more information, visit: www.acticor-biotech.com

  Buy Side   Sell Side
  Number of
executions		 Number of
shares		 Traded volume
in EUR		   Number of
executions		 Number of
shares		 Traded volume
in EUR
Total

631

59 726

419 225.09

  

505

50 122

385 042.61
02/01/2023

2

101

717.10

  

3

416

2 978.56
03/01/2023

2

35

248.50

  

1

200

1 440.00
04/01/2023

4

416

2 941.12

  

3

326

2 314.60
05/01/2023

1

1

7.10

  

1

1

7.10
06/01/2023

6

410

2 878.20

  

1

1

7.08
09/01/2023

3

455

3 171.35

  

1

2

14.08
10/01/2023

1

23

162.38

  

7

672

4 771.20
11/01/2023

1

1

7.12

  

3

251

1 792.14
12/01/2023

–

–

–

  

6

300

2 166.00
13/01/2023

–

–

–

  

8

680

5 004.80
16/01/2023

–

–

–

  

4

250

1 850.00
17/01/2023

–

–

–

  

10

830

6 225.00
18/01/2023

1

1

7.50

  

7

751

5 707.60
19/01/2023

6

294

2 202.06

  

–

–

–
20/01/2023

4

31

229.40

  

–

–

–
23/01/2023

2

20

148.00

  

1

1

7.50
24/01/2023

4

122

902.80

  

2

9

66.96
25/01/2023

6

135

999.00

  

1

1

7.44
26/01/2023

2

51

374.34

  

2

3

22.11
27/01/2023

4

19

139.46

  

9

648

4 872.96
30/01/2023

–

–

–

  

9

1 634

12 467.42
31/01/2023

6

250

1 900.00

  

5

753

5 820.69
01/02/2023

–

–

–

  

18

2 963

23 704.00
02/02/2023

–

–

–

  

13

1 461

12 111.69
03/02/2023

3

321

2 767.02

  

17

2 389

20 927.64
06/02/2023

–

–

–

  

25

2 948

27 652.24
07/02/2023

2

500

5 000.00

  

21

2 002

20 160.14
08/02/2023

–

–

–

  

13

1 250

12 812.50
09/02/2023

1

80

832.00

  

17

1 500

15 795.00
10/02/2023

14

1 303

13 876.95

  

10

1 500

16 350.00
13/02/2023

14

1 014

10 555.74

  

3

106

1 127.84
14/02/2023

46

4 097

39 126.35

  

–

–

–
15/02/2023

5

545

5 150.25

  

8

750

7 125.00
16/02/2023

2

12

112.80

  

14

2 001

19 709.85
17/02/2023

9

750

7 402.50

  

6

500

4 975.00
20/02/2023

4

1 000

9 650.00

  

–

–

–
21/02/2023

–

–

–

  

3

66

640.20
22/02/2023

7

250

2 400.00

  

1

184

1 784.80
23/02/2023

1

250

2 375.00

  

1

250

2 400.00
24/02/2023

2

250

2 400.00

  

1

250

2 425.00
27/02/2023

12

1 812

16 724.76

  

5

327

3 070.53
28/02/2023

3

676

5 948.80

  

2

250

2 250.00
01/03/2023

19

1 816

15 926.32

  

3

250

2 200.00
02/03/2023

10

363

3 183.51

  

2

251

2 208.80
03/03/2023

2

425

3 765.50

  

5

752

6 820.64
06/03/2023

18

1 108

9 839.04

  

4

131

1 190.79
07/03/2023

13

1 173

10 040.88

  

2

17

149.60
08/03/2023

9

945

7 720.65

  

1

1

8.50
09/03/2023

25

3 889

26 289.64

  

4

500

3 400.00
10/03/2023

1

250

1 675.00

  

–

–

–
13/03/2023

21

2 250

14 355.00

  

–

–

–
14/03/2023

3

257

1 619.10

  

1

15

96.00
15/03/2023

20

2 119

12 459.72

  

4

743

4 458.00
16/03/2023

11

1 355

7 791.25

  

5

791

4 635.26
17/03/2023

6

645

3 637.80

  

6

703

4 014.13
20/03/2023

3

518

2 869.72

  

2

336

1 891.68
21/03/2023

1

250

1 425.00

  

4

250

1 435.00
22/03/2023

1

1

5.70

  

4

171

991.80
23/03/2023

–

–

–

  

9

1 256

7 661.60
24/03/2023

6

500

3 125.00

  

8

1 023

6 649.50
27/03/2023

1

26

161.20

  

2

500

3 165.00
28/03/2023

6

250

1 575.00

  

–

–

–
29/03/2023

3

474

2 962.50

  

2

2

12.72
30/03/2023

6

636

3 968.64

  

1

1

6.32
31/03/2023

12

1 618

9 708.00

  

1

1

6.30
03/04/2023

1

4

24.00

  

4

557

3 436.69
04/04/2023

4

297

1 826.55

  

6

435

2 714.40
05/04/2023

4

270

1 671.30

  

1

1

6.30
06/04/2023

6

188

1 146.80

  

1

1

6.16
11/04/2023

–

–

–

  

2

250

1 550.00
12/04/2023

–

–

–

  

5

250

1 565.00
13/04/2023

1

250

1 550.00

  

3

140

876.40
14/04/2023

4

201

1 226.10

  

2

11

68.09
17/04/2023

3

192

1 190.40

  

3

91

569.66
18/04/2023

10

848

5 172.80

  

2

21

130.20
19/04/2023

13

1 350

7 911.00

  

1

4

24.40
20/04/2023

3

237

1 374.60

  

–

–

–
21/04/2023

6

350

2 026.50

  

2

200

1 160.00
24/04/2023

1

10

57.20

  

4

420

2 448.60
25/04/2023

–

–

–

  

6

193

1 136.77
26/04/2023

5

352

2 034.56

  

2

83

481.40
27/04/2023

9

1 296

7 218.72

  

1

250

1 400.00
28/04/2023

3

413

2 230.20

  

2

20

108.60
02/05/2023

3

251

1 340.34

  

7

182

990.08
03/05/2023

8

1 000

5 300.00

  

5

164

885.60
04/05/2023

8

357

1 881.39

  

–

–

–
05/05/2023

–

–

–

  

6

813

4 438.98
08/05/2023

–

–

–

  

9

876

5 037.00
09/05/2023

–

–

–

  

14

1 774

10 839.14
10/05/2023

5

250

1 525.00

  

2

17

103.70
11/05/2023

5

500

3 025.00

  

4

443

2 706.73
12/05/2023

5

443

2 684.58

  

2

64

391.68
15/05/2023

10

558

3 353.58

  

2

500

3 050.00
16/05/2023

7

748

4 510.44

  

3

738

4 523.94
17/05/2023

–

–

–

  

3

153

948.60
18/05/2023

4

636

3 828.72

  

–

–

–
19/05/2023

5

287

1 750.70

  

–

–

–
22/05/2023

9

927

5 580.54

  

–

–

–
23/05/2023

5

543

3 198.27

  

1

1

6.06
24/05/2023

4

250

1 450.00

  

2

499

2 969.05
25/05/2023

5

1 000

5 730.00

  

4

201

1 179.87
26/05/2023

4

99

564.30

  

3

161

924.14
29/05/2023

3

152

866.40

  

2

59

338.66
30/05/2023

6

327

1 863.90

  

3

250

1 435.00
31/05/2023

7

1 173

6 580.53

  

3

450

2 596.50
01/06/2023

–

–

–

  

1

1

5.60
02/06/2023

–

–

–

  

5

749

4 261.81
05/06/2023

2

196

1 117.20

  

4

200

1 144.00
06/06/2023

7

760

4 301.60

  

2

171

981.54
07/06/2023

2

254

1 422.40

  

1

24

136.80
08/06/2023

6

490

2 753.80

  

3

245

1 396.50
09/06/2023

2

250

1 400.00

  

–

–

–
12/06/2023

9

1 363

7 169.38

  

2

450

2 403.00
13/06/2023

6

1 250

6 425.00

  

3

59

307.98
14/06/2023

4

250

1 275.00

  

–

–

–
15/06/2023

3

251

1 280.10

  

1

1

5.14
16/06/2023

3

251

1 280.10

  

8

858

4 504.50
19/06/2023

1

20

108.00

  

3

384

2 112.00
20/06/2023

5

222

1 198.80

  

1

1

5.42
21/06/2023

4

309

1 650.06

  

3

35

191.45
22/06/2023

3

425

2 278.00

  

3

52

282.88
23/06/2023

5

188

985.12

  

3

56

302.40
26/06/2023

3

138

717.60

  

–

–

–
27/06/2023

2

255

1 326.00

  

3

250

1 325.00
28/06/2023

5

251

1 330.30

  

2

2

10.72
29/06/2023

2

250

1 325.00

  

3

192

1 052.16
30/06/2023

4

501

2 725.44

  

–

–

–

 

Contacts

ACTICOR BIOTECH
Gilles AVENARD, MD

CEO and Founder

gilles.avenard@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

General Manager and CSO

Sophie.binay@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

NewCap
Mathilde BOHIN / Quentin MASSÉ

Investor Relations

acticor@newcap.eu
T. : +33 (0)1 44 71 94 95

NewCap
Arthur ROUILLÉ

Media Relations

acticor@newcap.eu
T. : +33 (0)1 44 71 00 15

Related articlesMore from author